Actively Recruiting
Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity
Led by Second Affiliated Hospital, School of Medicine, Zhejiang University · Updated on 2025-12-19
66
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a prospective, randomized, open-label clinical trial enrolling 66 adults with simple obesity who have not used weight-loss medications for at least 3 months. Participants will receive semaglutide, tirzepatide, or metformin for 24 weeks. Changes in "biological (epigenetic) age" will be assessed using the iWatchAge DNA methylation age test, while simultaneously monitoring improvements in aging-related biomarkers such as inflammatory factors, metabolic parameters, and body composition. The aim is to determine whether incretin-based therapies can reverse or slow obesity-related accelerated epigenetic aging and to provide new clinical evidence for interventions targeting obesity and aging.
CONDITIONS
Official Title
Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 to 75 years
- Diagnosed with simple obesity with a BMI of 30 kg/m² or higher
- No use of anti-obesity medications in the past 3 months
- Able and willing to follow study procedures and complete follow-up
- Provided written informed consent
You will not qualify if you...
- Secondary obesity due to endocrine disorders like Cushing's syndrome or hypothyroidism
- Use of anti-obesity drugs or participation in weight-loss programs within the past 3 months
- Diagnosis of type 1 or type 2 diabetes requiring hypoglycemic treatment
- History of pancreatitis, severe gastrointestinal disease, or bariatric surgery
- Severe cardiovascular, liver, kidney, or psychiatric conditions affecting participation
- Pregnant or breastfeeding, or planning pregnancy during the study
- Currently in another clinical trial
- Any condition judged by investigators as unsuitable for participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Second Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, China
Actively Recruiting
Research Team
C
Chao Zheng
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here